|
BEND3 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.19449999999677E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.30049999999849E-05 |
| Normal-vs-Stage2 |
1.402570E-03 |
| Normal-vs-Stage3 |
2.178400E-03 |
| Normal-vs-Stage4 |
1.457540E-02 |
| Stage1-vs-Stage2 |
5.620000E-01 |
| Stage1-vs-Stage3 |
7.220000E-01 |
| Stage1-vs-Stage4 |
2.464000E-01 |
| Stage2-vs-Stage3 |
4.569200E-01 |
| Stage2-vs-Stage4 |
1.946210E-01 |
| Stage3-vs-Stage4 |
5.093200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.14270000000028E-05 |
| Normal-vs-AfricanAmerican |
2.022600E-04 |
| Normal-vs-Asian |
1.006490E-02 |
| Caucasian-vs-AfricanAmerican |
1.933800E-01 |
| Caucasian-vs-Asian |
6.695400E-01 |
| AfricanAmerican-vs-Asian |
1.183840E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.602360E-03 |
| Normal-vs-Female |
1.88160999999853E-05 |
| Male-vs-Female |
3.803600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.425070E-04 |
| Normal-vs-Age(41-60Yrs) |
6.964300E-04 |
| Normal-vs-Age(61-80Yrs) |
3.154600E-04 |
| Normal-vs-Age(81-100Yrs) |
3.298400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.079000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.295600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.162600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.545400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.638400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.675210E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.255700E-02 |
| Classical-VS-Follicular |
6.003900E-03 |
| Classical-VS-Other |
1.597240E-01 |
| Classical-VS-Normal |
2.79069999997716E-07 |
| Tall-VS-Follicular |
9.080400E-01 |
| Tall-VS-Other |
5.711000E-01 |
| Tall-VS-Normal |
9.206100E-02 |
| Follicular-VS-Other |
6.594200E-01 |
| Follicular-VS-Normal |
7.219900E-02 |
| Other-VS-Normal |
7.300000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.73050000000275E-05 |
| Normal-vs-N1 |
6.982000E-02 |
| N0-vs-N1 |
5.176400E-02 |
|
|
